FeesSafety
Pluang+

Sanofi starts building advanced insulin factory in Frankfurt to secure global supply by 2032

Company Fundamentals
19 Oct 2026, 13:30 WIB
GlobeNewsWire
View Source
Bullish
Sanofi starts building advanced insulin factory in Frankfurt to secure global supply by 2032

Sanofi has begun construction of a cutting-edge insulin manufacturing facility at its BioCampus in Frankfurt, Germany, aiming for full production by 2032. This new plant will enhance Sanofi's ability to supply insulin reliably to millions worldwide, leveraging advanced automation and AI technologies. The facility, covering 36,000 square meters, will be one of Europe's largest and most advanced, supporting Sanofi's long-term commitment amid rising global diabetes cases. The project received public support from German authorities and reflects Sanofi's strategy to maintain a strong insulin supply chain for decades.

Following Sanofi's announcement of its new insulin manufacturing facility in Germany, the company's shares are trading at USD 39.96 on Pluang as of Oct 19, 2026 17:11 WIB, down 1.60% for the day. Sanofi holds a market capitalization of $96.64 billion and offers a dividend yield of 5.96%, reflecting its established position in the health sector. The typical hold time for SNY on Pluang is 94 days, indicating steady investor interest.

More News (SNY)

Sanofi's Pompe disease drug shortage persists over 3 months due to manufacturing issues, risking patient health.

Sanofi's Pompe disease drug shortage persists over 3 months due to manufacturing issues, risking patient health.

Sanofi is facing a drug shortage for its Pompe disease treatments due to manufacturing problems at its Ireland facility, causing infusion cancellations for patients. The shortage has lasted over three months, with shipping delays expected to continue...

Market News
Bearish
1 day ago
EU approves Sanofi's new-generation rabies vaccine VaxRabeo for all ages

EU approves Sanofi's new-generation rabies vaccine VaxRabeo for all ages

Sanofi's new rabies vaccine, VaxRabeo, has been approved by the European Commission for use in all age groups for both pre-exposure and post-exposure prophylaxis. The vaccine, made with advanced Vero cell technology, offers longer shelf life and bett...

Market News
Bullish
1 day ago
EU approves Sanofi's next-gen rabies vaccine VaxRabeo for all ages, enhancing prevention and treatment options.

EU approves Sanofi's next-gen rabies vaccine VaxRabeo for all ages, enhancing prevention and treatment options.

Sanofi's new rabies vaccine, VaxRabeo, has received European Commission approval for use in all age groups for both pre-exposure and post-exposure prophylaxis. The vaccine uses advanced Vero-cell technology, offering improved safety, longer shelf lif...

Market News
Bullish
1 day ago
FDA approves Infilbray, first oral drug for neurological symptoms of Type 3 Gaucher disease

FDA approves Infilbray, first oral drug for neurological symptoms of Type 3 Gaucher disease

The FDA has approved Infilbray (venglustat), a once-daily oral medication that crosses the blood-brain barrier to treat neurological symptoms of Type 3 Gaucher disease (GD3) in adults and children over 15 kg. GD3 is a rare genetic disorder causing pr...

Market News
Bullish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App